Three Research Articles Cite Cleanascite™ in Bile Proteomics The first citation is: Annarita Farina, Jean-Marc Dumonceau, Paola Antinori, Isabelle Annessi-Ramseyer, Jean-Louis Frossard, Denis F. Hochstrasser, Myriam Delhaye, Pierre Lescuyer. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses. Biochimica et Biophysica Acta 1844 (2014) 1018–1025 In brief, the article’s authors aimed at identifying new cancer biomarkers by comparing proteomic analysis of bile collected from patients with a malignant or benign biliary stenosis. The article states “For sample preparation, bile samples were centrifuged at 16,000g for 10 minutes. Each supernatant was delipidated with Cleanascite…” The second citation is: Natalija Lukic, Rémy Visentin, Myriam Delhaye, Jean-Louis Frossard, Pierre Lescuyer, In brief, the article’s authors acknowledged that the complexity of bile and the presence of molecules interfering with protein analysis represent an obstacle for quantitative proteomic studies in bile samples. In this study, differential centrifugation was used as a preliminary step in a quantitative proteomic workflow involving iTRAQ labeling. Sample preparation for proteomic analysis was as follows: The third citation is: Elisa Danese, PhD, Orazio Ruzzenente, BS, Andrea Ruzzenente, MD, PhD, Calogero Iacono, MD, Francesca Bertuzzo, MD, Matteo Gelati, MT, Simone Conci, MD, Sharon Bendinelli, MT, Giada Bonizzato, MT, Alfredo Guglielmi, MD, Gian Luca Salvagno, MD Giuseppe Lippi, MD, and Gian Cesare Guidi, MD. Assessment of bile and serum mucin5AC in cholangiocarcinoma: Diagnostic performance and biologic significance. The author’s aim was to improve the biologic relevance of the mucin MUC5AC in malignant and benign biliary disorders by comparing its diagnostic performance in both bile and serum samples of patients with cholangiocarcinoma (CCA) or benign biliary disorders. “I am excited by the number of recent research articles on bile proteomics; 7 in the last 2 years alone. Clearly the excellent selectivity profile that Cleanascite™ provides is making its use routine whenever bile characterization requires complex analysis.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group. Cleanascite™ selectively removes lipids, cell debris, lipoproteins, impurities from cohn paste, transgenic milk, egg yolk and biological samples for pretreatment and clarification of samples. The reagent is a solid-phase, non-ionic adsorbent supplied as a suspension in saline, ready for use. Simply add, centrifuge and/or filter. The clarified supernatant is ready for subsequent downstream processing or analysis.
For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at About Biotech Support Group LLC Contact: Posted on Date: Wed, 09/17/2014 |

- About
- Products
- Hemoglobin Removal Kits
- Lipid Removal & Clarification
- Urine Protein & Low Abundance Enrichment
- Class Specific Enrichment
- Sample Prep Mass Spectrometry
- Functional & Chemical Proteomics
- Genomic Sample Prep
- Accessories
- Technical Resources
- References
- Publications & Reports
- FAQs
- Case Studies
- NRicher™ Bead Platform Provides Unique Sub-Proteome Biases And Fit For Purpose Opportunities for Targeted LC-MS Quantification
- BSG Products To Assist in Analyzing Macrophage Polarization
- Ectodomain Shedding and Enrichment of the Soluble Membrane Proteome
- Investigate out of the Venn Diagram box
- Methods to selectively deplete or purify Hemoglobin from Dried Blood Spots (DBS)
- The Utility of HemoVoid™ is Demonstrated in 3 Proteomic Investigations Identifying Potential Disease Specific Biomarkers
- The 4 common features of our sample prep products, known as the BSG Advantage, are highlighted in a selection of journal references.
- AlbuVoid™ Workflows Advance Cell Secretome Proteomics
- Lipid Removal for Phenotypic Cell Response in Cancer Research
- The Influence of Sample Prep Bias on LC-MS Targeted Peptide Quantification in Serum Proteomics
- Re-imagining proteomics for developing precision medicine biomarkers of the innate immune response in SARS-CoV-2
- Patent Application Describes New Proteomic Methods to Monitor Protease Inhibitor Function During Covid-19 Infections
- Efficient Hemoglobin Removal Advances Red Cell Proteomics Offering Many New Insights Into Inflammation and Infectious Disease
- The Potential for New Blood Biomarkers in the Management of COVID-19 Disease
- Establishing the Utility of HemoVoid™ and HemogloBind™ as Enrichment Tools for Proteomic Analysis of Red Cells and Whole Blood in Parkinson’s Disease
- Species Diversity Supported By BSG Products
- Poster Report Describes Loss of Functional Serpin Activity In Cancer Patient Blood
- AlbuVoid™️ PLUS & AlbuSorb™️ PLUS Evaluating Different Windows of Observation Solves The Many Challenges of Serum Proteomics
- Tackling the Challenges of Serum Proteomics
- Lipid Removal Sample Prep for Cell Response Applications
- Sample Prep for Proteomic Analysis of Saliva
- Biotech Support Group Featured in Book, "Functional Proteomics – Methods and Protocols"
- Sample Prep Liquid Biopsy Products Suitable for Proteomic Profiling of a Variety of Body Fluid Sample Types
- Albumin and High Abundance Depletion
- Using HemogloBind™ as a Hemoglobin Binding Reagent
- Diverse technologies available for researchers to selectively bind or enrich exosomes and extracellular vesicles.
- Stroma Liquid Biopsy™ Biomarkers Profile Pan-Cancer Dysregulation of the Serum Proteome
- Diverse Depletion and Enrichment Technologies Enhance Simplicity and Efficiency of Obtaining Quality Proteomic Information
- Use On-Bead Digestion to Improve Time Required for Serum Digestion
- Using AlbuVoid™ as a Serum Protein Enrichment Kit in Functional Proteomics
- Using Cleanascite™ as a Lipid Absorption and Clarification Reagent
- Using HemoVoid to Remove Hemoglobin Before Analysis
- Blog
- Contact
- Liquid Biopsy